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Abstract Mucin glycoprotein expression can be altered dur-
ing the carcinogenic process. The impact on the prognosis of
patients with colorectal cancer (CRC) is controversial. We
analyzed tumors from 381 patients for MUC1, MUC2,
MUC5AC, and MUC6 expression by immunohistochemical
staining, using tissue microarrays. Progression-free and
cancer-specific survival were determined using the Kaplan-
Meier method. Expression of intestinal mucin MUC2was lost
in 85 (23%) CRCs, and patients with MUC6-negative tumors
showed shorter progression-free survival (PFS, p = 0.043).
Gastric mucins MUC5AC and MUC6 showed high (>50 %)
aberrant expression in 28 (8 %) and 9 (2 %) cases, respective-
ly. High expression of MUC5AC was associated with longer
PFS (p = 0.055). High expression of MUC6 was associated
with 100 % PFS (p = 0.024) and longer cancer-specific sur-
vival (CSS, p = 0.043). MUC1 was expressed in 238 (64 %)
tumors and had no impact on outcome. When analysis was
restricted to stages II and III, loss of MUC2 was associated
with adverse outcome. Overexpression of both MUC5AC
and MUC6 significantly predicted favorable PFS and CSS.
In conclusion, loss of MUC2 expression proved to be a
predictor of adverse outcome, while the gain of aberrant
expression of MUC5AC and particularly of MUC6 was
associated with favorable outcome in CRC, notably in in-
termediate stages II and III.
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Introduction
Tumor stage reflected by the AJCC/UICC TNM system is
currently the strongest prognostic parameter for patients with
colorectal cancer (CRC) and is therefore used as basis for
therapeutic decisions [1]. However, patients with tumors of
the same pathologic stage may experience substantially
different clinical outcomes, especially in intermediate stages
of disease. Different patients may thus benefit from different
therapeutic and surveillance strategies [2, 3]. Hence, identifi-
cation of additional prognostic markers might be of interest to
improve stratification of patients.
Mucins are high-molecular-weight glycoproteins
expressed by epithelial tissues. They have a high content of
clustered oligosaccharides, forming a mucosal protection sys-
tem at the surface of the gastrointestinal tract [4]. Most of the
recent progress in understanding mucin biology is related to
the characterization of mucin proteins (apomucins) [5].
Mucins can be classified as secreted gel-forming mucins
(MUC2, MUC5AC, and MUC6), transmembrane mucins
(MUC1), and other mucins that do not fit into either class [5,
6]. Throughout the gastrointestinal tract, epithelial cells com-
monly synthesize more than one mucin, although a particular
mucin type may predominate in an organ-specific manner. For
example, MUC2 is characteristically observed in goblet cells
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of small and large bowel mucosa, whereas MUC5AC and
MUC6 are mainly expressed in gastric epithelium and are
rarely observed in the normal colon [5–7]. In contrast,
MUC1 is expressed on the apical surface of most epithelial
cells [8]. Of note, during neoplastic transformation and/or
progression, expression of specific mucins may be reduced
or the organ specificity lost, while new mucins may be
expressed aberrantly.
In colorectal tumors, several mucins have been analyzed, in
relation to the adenoma-carcinoma sequence, MUC1 and
MUC2 being the best characterized [4, 6–9]. However, data
on the clinical significance, particularly the potential prognos-
tic value of mucin expression in colorectal carcinoma (CRC)
are limited and contradictory [5, 6, 9, 10].
Therefore, our study aimed to comprehensively assess the
prevalence of MUC1, MUC2, MUC5AC, and MUC6 expres-
sion in a large cohort of CRC patients, its association with
various clinicopathological parameters such as T classifica-
tion, N classification, lymphovascular invasion, grade, tumor
border configuration, mismatch repair (MMR) status, as well
as patients’ progression-free and cancer-specific survival.
Patients and methods
Case selection
Case selection of our cohort has been described in detail pre-
viously [11]. Briefly, 400 CRC patients treated from January
1992 through December 2000 were randomly selected from
the CRC database of the Institute of Pathology, Medical
University of Graz, Austria. We excluded (1) patients with
T1 cancer treated by endoscopic polypectomy, (2) patients
that received neoadjuvant chemotherapy, (3) patients with
synchronous or metachronous invasive cancers originating
from the colorectum or other sites. In total, 381 resection
specimens from 400 patients (95%)were available for pathol-
ogy review. Of these, 215 were males (56 %) and 166 females
(44 %) (ratio 1.3:1) with a mean age of 68.5 years (median
70.1, range 27.6–93.1).
Stage I and II patients did not receive adjuvant therapy,
while stage III patients were treated with 5-fluorouracil/folic
acid according to the Mayo Clinic regimen [12]. Patients with
node-positive rectal cancer received adjuvant radiotherapy.
Follow-up chest X-ray and abdominal ultrasound were per-
formed at 6-month intervals for the first 3 years and yearly
thereafter. Moreover, laboratory testing (blood count, liver
enzymes, CEA, and CA19–9) was performed at 3-month in-
tervals for the first 3 years and 6-month intervals thereafter.
Patients with rectal cancer underwent pelvic computerized
tomography every 12 months. Patients were followed after
resection until death or time of last follow-up. Disease
progression was defined as local tumor recurrence or devel-
opment of distant metastasis.
Pathological evaluation
Original histopathological slides were independently re-
evaluated by two gastrointestinal pathologists (M.J.P. and
C.L.). Tumors located in the cecum and transverse colon were
defined as right-sided cancers, while tumors located in the left
colonic flexure down to the sigmoid colon were defined as
left-sided cancers. Tumors located at the rectosigmoid junc-
tion or in the rectum were defined as rectal cancers. Tumor
stage was assessed according to the AJCC/UICC 2009 issue
of the TNM classification [13]. Histological tumor type and
tumor grade were established according to the WHO guide-
lines [14]. The presence of lymph and/or blood vessel inva-
sion was assessed as carcinoma cells present in vessels with an
unequivocal endothelial lining (lymphatic invasion) or in ves-
sels with a thick vascular wall and red blood cells in the lumen
(blood vessel invasion). Tumor border configurations were
evaluated according to the Jass classification (expanding vs
infiltrative) [15]. The extent of tumor budding (presence of
isolated single cells or small clusters of tumor cells in the
stroma at the invasive tumor margin) was assessed on H&E-
stained slides in a field in which budding intensity was max-
imal [16]. The number of budding foci was scored as low
grade (<10 budding foci) or high grade (>9 budding foci) [17].
Immunohistochemistry
A tissue microarray technique was used for immunohisto-
chemical evaluation as described previously [18]. Briefly, tis-
sue microarrays (TMAs) were constructed using a manual
tissue-arraying instrument (Beecher, Silver Spring, MD,
USA). Between 3 and 14 (mean 5.03, median 5) cylindrical
core biopsies, 0.6 mm in diameter, were taken from different
sites of each tumor and arrayed in a recipient paraffin TMA.
For immunohistichemical staining, 4 μm TMA sections
were treated with 1 % H2O2, subjected to antigen retrieval
and subsequently incubated for 30 min with primary antibod-
ies using automated staining systems (Universal Staining
System, DakoCytomation, Glostrup, Denmark, or
BenchMark, Ventana Medical Systems, S.A, Illkirch
CEDEX, France). Details on primary antibodies, dilution,
and epitope retrieval are listed in Table 1. The reaction was
visualized by the Dako EnVision system detection kit, or the
ultraVIEW Universal DAB detection kit (Ventana). Goblet
cells in adjacent non-neoplastic colonic mucosa served as pos-
itive control for MUC2, slides of gastric cancer, known to
express MUC1, MUC5AC, and MUC6 served as positive
control for MUC1, MUC5AC, and MUC6. Negative con-
trols included omission of the primary antibodies and in-
cubation with Dako ChemMate Antibody Diluent (code
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no. S 2022) or Ventana Antibody Diluent (catalog no. 251–
018), respectively.
Immunoreactivity of MUC1, MUC2, MUC5AC, and
MUC6 was assessed by two investigators (J.B. and
N.I.S.), who were blinded to clinicopathologic data.
Distinct membranous and/or granular cytoplasmic staining
was considered positive. Immunoreactivity was semiquan-
titatively categorized as “negative” (0 % of tumor cells
positive) as “low” (<50 % of tumor cells positive) or as
“high” (>50 % of tumor cells positive). Each tumor was
scored by assessing the average immunoreactivity of the
TMA cores. For validation of staining results obtained
from TMA slides, we performed immunohistochemistry
on corresponding whole sections in selected cases (com-
pare below).
MMR status was assessed as described earlier, using anti-
bodies directed against MLH1, MSH2, and MSH6 [18]. The
loss of immunoreactivity for at least one of the three markers
characterized MMR-deficient tumors [19].
Statistical analysis
Associations with T classification, N classification,
AJCC/UICC stage, grade, lymphovascular invasion, MMR
status, location, tumor type, tumor budding, and tumor border
configuration were analyzed using the chi-squared test or
Fisher’s exact test. Cause of death was determined by treating
physicians and/or by chart review and was corroborated by
death certificates if available. Progression-free/disease-free
(PFS) and cancer-specific survival (CSS) were investigated
using the Kaplan-Meier method and compared by the log-
rank test. For bivariate testing, Cox proportional hazards
regression models were performed. Statistical calculations
were performed using R version 3.2.0 (R Foundation for
Statistical Computing, Vienna, Austria; http://www.R-
project.org/) or with SPSS version 20.0 (IBM, Armonk,
NY, USA). All reported p values were two-sided with sig-
nificance at p < 0.05.
Results
Tumor characteristics
We classified 28 (7%) tumors as pT1, 70 (18 %) as pT2, 218
(57 %) as pT3, and 65 (17 %) as pT4. Lymph node metastases
were detected in 165 (43 %) cases. Tumor grades were G1 in
121 (32 %), G2 in 138 (36 %), and G3 in 122 (32 %) cases.
Regarding tumor type, 317 (83 %) cases were adenocarci-
nomas and 44 (12 %) were mucinous adenocarcinomas. The
remaining tumors presented with rare histological subtypes
such as 13 (3 %) undifferentiated carcinomas, 3 signet-ring
cell, 2 medullary, 1 amphicrine, and 1 adenosquamous carci-
noma. Lymphovascular invasion was recorded in 158 (41 %)
tumors.
High expression of MUC1 was observed in 46 (12%) and
low expression in 192 (52 %) tumors, while 134 (36 %) tu-
mors were negative for MUC1 (Fig. 1a). High expression of
MUC2 was observed in 61 (16 %) and low expression in
225 (61 %) tumors, while expression of MUC2 was lost in
85 (23 %) cases (Fig. 1b). High aberrant expression of
MUC5AC was observed in 28 (8 %) and low expression
in 155 (42 %) tumors, while 189 (51 %) tumors were neg-
ative for MUC5AC (Fig. 1c). High expression of MUC6
was observed in 9 (2 %) and low expression in 99 (27 %)
tumors, while 264 (71 %) lacked MUC6 expression
(Fig. 1d).
Expression of MUC1 was significantly associated with T
and N classification, AJCC/UICC stage, and tumor differen-
tiation and inversely correlated with mucinous adenocarcino-
ma histological type. MUC2, MUC5AC, and MUC6 were
significantly associated with MMR status and tumor border
configuration. Additionally, MUC2 expression was associated
with mucinous differentiation and inversely correlated with
lymphovascular invasion and tumor differentiation.
MUC5AC expression correlated with tumor location and mu-
cinous subtype. MUC6 inversely correlated with tumor differ-
entiation and mucinous adenocarcinoma subtype (Table 2).
MUC5AC expression significantly correlated with MUC2
Table 1 Antibodies used for immunohistochemical staining
Antibody Clone Dilution Epitope-retrieval Chromogen Source
MUC1 Ma695 1:100 HIER DAB Novocastra, Newcastle upon Tyne, UK
MUC2 Ccp58 1:50 HIER DAB Novocastra
MUC5AC 45 M1 1:100 MW, Tris–HCl urea AEC Abnova, Taipei, Taiwan
MUC6 MCN6.01 1:100 MW, Tris–HCl urea AEC Neomarker, CA, USA
MLH1 G168–15 1:50 MW, buffer pH 9 DAB Biocare, Concorde, CA, USA
MSH2 G219–1129 1:50 Buffer CC1 standard DAB Ventana, Tucson, AZ, USA
MSH6 BC-44 1:50 Buffer CC1 mild DAB Biocare
AEC 3-amino-9-ethylcarbazole, buffer pH 9 target retrieval solution, Dako (S2367), CC1 cell conditioning 1 (Ventana 950–124 SL), DAB
3,3′-diaminobenzidine, HIER heat induced epitope retrieval solution (Dako, code no. K 5205), 40 min 98 °C, MW microwave
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and MUC6, while MUC6 expression significantly correlated
with expression of MUC1 and MUC5AC (Table 3).
For validation of TMA staining results, a subset of cases
with negative and low and high expressions of MUC1,
MUC2, MUC5AC, and MUC6 was analyzed on correspond-
ing whole sections. Staining results obtained from TMA slides
were confirmed in all analyzed cases (Fig. 2).
Survival analysis
For 350 out of 381 (92 %) patients, follow-up data were
available. Progressive disease was observed in 141 (40 %)
patients after a median (mean) follow-up of 45 months (56)
(range 1–182). Eleven patients were alive with metastatic
disease at the end of follow-up, 118 (34 %) patients died
from cancer. Seven patients were without evidence of dis-
ease after metastasectomy. Five patients that had presented
in poor condition due to advanced disease died within
30 days of surgery. Mean time to progression was
15 months (median 7, range 0–88) [11].
MUC1
Disease progression occurred in 43 % of patients with tu-
mors positive (high or low) for MUC1, compared with
36 % of patients with tumors negative for MUC1
(p = 0.2). Actuarial 5-year PFS rates were 56 and 64 %,
respectively. In addition, 35 % of patients with MUC1-
positive and 32 % of patients with MUC1-negative tumors
died of disease (p = 0.48). Actuarial 5-year CSS rates were
63 and 67 %, respectively.
MUC2
Disease progression occurred in 52% of patients with tumors
negative for MUC2 compared with 37 % of patients with
tumors positive (high or low) for MUC2 (p = 0.043;
Fig. 3a). Actuarial 5-year PFS rates were 50 and 62%, respec-
tively. In addition, 42 % of patients with MUC2-negative and
32 % of patients with MUC2-positive tumors died of disease
(p = 0.15; Fig. 3b). Actuarial 5-year CSS rates were 60 and
66 %, respectively.
MUC5AC
Disease progression occurred in 37% of patients with tumors
positive (high or low) for MUC5AC, compared with 44 % of
patients with tumors negative for MUC5AC (p = 0.46).
Actuarial 5-year PFS rates were 63 and 56 %, respectively.
In addition, 30 % patients with MUC5AC-positive and 44 %
of patients with MUC5AC-negative tumors died of disease
(p = 0.28). Actuarial 5-year CSS rates were 67 and 62 %,
respectively. Of note, the extent of MUC5AC expression
was found to be related to disease outcome, that is, only
20 % of patients with high (>50 % of tumor cells)
MUC5AC expression experienced disease progression, com-
pared with 42 % of patients with low or absent MUC5AC
expression (p = 0.055; Fig. 3c). Actuarial 5-year PFS rates
Fig. 1 Examples of
immunohistochemical staining of
MUC1 (×200, a), MUC2 (×200,
b), MUC5AC (×200, c), and
MUC6 (×200, d) using TMA
slides
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were 79 and 58 %, respectively. In addition, 20 % of patients
with highMUC5AC expression and 38% of patients with low
or absent MUC5AC expression died of disease (p = 0.18;
Fig. 3d). Actuarial 5-year CSS rates were 77 and 64 %,
respectively.
MUC6
Disease progression occurred in 39 % of patients with
tumors positive (high or low) for MUC6, compared with
99 out of 243 (41 %) patients with tumors negative for
MUC6 (p = 0.83). Actuarial 5-year PFS rates were 61
and 59 %, respectively. In addition, 30 % of patients with
MUC6-positive and 35 % of patients with MUC6-negative
tumors died of disease (p = 0.25). Actuarial 5-year CSS
rates were 70 and 62 %, respectively. Again, the extent of
expression was found to be related to disease outcome,
that is, disease progression occurred in 41 % of patients
with low or absent MUC6 expression, while none of the
nine patients with high MUC6 expression experienced
Table 3 Interrelations of different mucins expressed in CRC
MUC2 MUC5AC MUC6
Negative (%) Low (%) High (%) Negative (%) Low (%) High (%) Negative (%) Low (%) High (%)
MUC1
0 33 (25) 71 (53) 29 (22) 77 (58) 49 (37) 8 (6) 119 (89) 15 (11) 0 (0)
<50 % 43 (22) 120 (63) 29 (15) 92 (48) 87 (45) 13 (7) 120 (63) 69 (36) 3 (2)
>50 % 9 (20) 34 (74) 3 (7) 20 (44) 19 (41) 7 (15) 25 (54) 15 (33) 6 (13)
p 0.0797 0.106 0.001
MUC2
0 66 (77) 18 (21) 2 (2) 76 (88) 9 (11) 1 (1)
<50 % 109 (48) 104 (46) 13 (6) 143 (63) 77 (34) 7 (3)
>50 % 16 (26) 32 (53) 13 (21) 47 (77) 13 (21) 1 (2)
p 0.001 0.001
MUC5AC
0 178 (93) 13 (7) 0 (0)
<50 % 75 (48) 79 (51) 1 (1)
>50 % 13 (46) 7 (25) 8 (29)
p 0.001
Fig. 2 Examples of TMA
validation using whole sections
(showing identical staining
results): low expression of MUC1
(×100, a), low expression of
MUC2 (×100, b), high expression
of MUC2 (×40, c), and negative
staining for MUC5AC (×40, d).
Roundish tissue defects owing to
punch-out of tumor for TMA
generation are included in all
images
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progressive disease (p = 0.024; Fig. 3e). Actuarial 5-year
PFS rates were 100 and 58 %, respectively. In addition,
34 % of patients with low or absent MUC6 expression and
no patient with high MUC6 expression died of disease
(p = 0.043; Fig. 3f). Actuarial 5-year CSS rates were 100






































































































































































Fig. 3 Progression-free (a, p = 0.043) and cancer-specific (b, p = 0.15)
survival of patients with colorectal cancer related to the extent of MUC2
expression (present vs. absent). Progression-free (c, p = 0.055) and
cancer-specific (c, p = 0.18) survival of patients with colorectal cancer
related to the extent of MUC5AC expression (high vs. low expression).
Progression-free (e, p = 0.024) and cancer-specific (f, p = 0.043) survival
of patients with colorectal cancer related to the extent of MUC6
expression (high vs. low expression)
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Combined analysis
Accordingly, patients with tumors that showed either pre-
served MUC2 expression and/or high expression of
MUC5AC and/or a high expression of MUC6 had longer
PFS (p = 0.031) but not CSS (p = 0.11) than patients lacking
those features.
Stages II and III
Loss of intestinal mucin (MUC2) was also related to shorter
PFS (p = 0.003, Fig. 4a) and CSS (p = 0.089, Fig. 4b), when
analysis was restricted to patients with intermediate stages of
disease, that is, AJCC/UICC stages II and III. Likewise, gain
of gastric mucin (MUC5AC and MUC6) was related to im-
proved outcome. Specifically, highMUC5AC expression pre-
dicted favorable PFS (p = 0.015, Fig. 4c) and CSS (p = 0.033,
Fig. 4d), as did high MUC6 expression (PFS: p = 0.03,
Fig. 4e; CSS: p = 0.047, Fig. 4f). Finally, patients with stage
II and III disease with tumors that showed either preserved
MUC2 expression and/or high expression of MUC5AC and/
or a high expression of MUC6 had longer PFS (p = 0.0018)
and CSS (p = 0.062) than patients lacking those features.
MMR-positive and MMR-negative patients
SinceMMR expression is known to be a confounder of mucin
expression, we analyzed MMR positive and negative patients
separately. In patients with MMR proficient tumors (n = 350),
loss of MUC2 was associated with shorter PFS (p = 0.024)
and CSS (p = 0.095). High expression of MUC5AC was
related to shorter PFS (p = 0.047), while the association
of MUC5AC with decreased CSS was not statistically sig-
nificant (p = 0.12). High expression of MUC6 was associ-
ated with decreased PFS (p = 0.023) and CSS (p = 0.042).
MUC1 expression showed no impact on PFS (p = 0.28) or
CSS (p = 0.65). In patients with MMR-deficient tumors
(n = 23), no significant impact on either PFS or CSS was
observed.
Additionally, we performed bivariate Cox proportional
hazards regression models including MMR status and mucin
expression. MUC2 negativity was significantly associated
with PFS (HR 1.46, 95 % CI 1.01–2.12, p = 0.043), while
MMR deficiency was not (HR 1.04, 95 % CI 0.48–2.22,
p = 0.93). No association with CSS was observed for both
markers. High expression of MUC5AC showed a trend to-
ward improved PFS (HR 0.44, 95 % CI 0.18–1.07,
p = 0.07), while no association of MMR deficiency with
PFS was observed (HR 1.04, 95 % CI 0.49–2.23, p = 0.92).
Again, no association with CSS was observed for both
markers. Bivariate Cox regression analyses could not be per-
formed for MUC6 due to low case numbers.
When only stage II and III patients were analyzed in bivar-
iate Cox regression models, presence of MUC2 showed sig-
nificant association with PFS (HR 2.05, 95 % CI 1.29–2.35,
p = 0.002), while MMR deficiency did not (HR 1.12, 95 % CI
0.35–3.55, p = 0.85). A trend toward shorter CSS was ob-
served for presence of MUC2 (p = 0.07), but not for MMR
deficiency (p = 0.95). High expression of MUC5AC was sig-
nificantly associated with PFS (HR 0.13, 95 % CI 0.02–0.91,
p = 0.04), while no association of MMR deficiency with PFS
was observed (HR 1.06, 95 % CI 0.35–3.37, p = 0.92). High
MUC5AC expression showed a trend toward inferior CSS
(p = 0.06), while no association of MMR deficiency
(p = 0.89) with CSS was noted.
Discussion
Mucins have an important function as protective layer for
epithelial tissues in the gut and elsewhere in the body. It is
well known that during carcinogenesis mucins can be lost
or aberrantly expressed in locations where they are not
present constitutively. They might be involved in tumor
progression and spread. However, the prognostic value of
aberrant mucin expression in CRC is controversial [5, 6,
9, 10].
In this study, we show that the loss of intestinal mucin
MUC2 predicted adverse outcome, while the gain of gastric
differentiation, as documented by aberrant MUC5AC and
particularly MUC6 expression: was associated with favorable
outcome. In addition, expression of MUC1 proved to be a
marker of tumor progression and lymph node metastasis. A
significant association betweenMUC1 expression and surviv-
al was, however, not detected in our cohort.
Previous publications have reported impact of MUC1 ex-
pression on tumor progression and also on survival [10,
20–24]. For instance, MUC1 expression has been related to
higher TNM stage and reduced recurrence-free and overall
survival in 206 patients with CRC [22]. Duncan et al. [23]
found no association with T or N classification, but also re-
ported a significant reduction of CSS for MUC1-positive tu-
mors. Lugli et al. [10] analyzed a large number of tumors and
observed, similar to our data, a positive association of MUC1
with T classification, but not with survival in MMR-proficient
tumors. They also found no association with clinicopatholog-
ical parameters inMLH1-negative cases. Hence, whileMUC1
expression appears to be related to tumor stage, its impact on
survival remains controversial.
MUC2 is a colonic mucin usually expressed by goblet
cells. It is enriched in mucinous adenocarcinoma and can be
lost during the carcinogenic process in conventional adeno-
carcinoma. Similar to MUC1, previous data about the prog-
nostic impact of MUC2 are conflicting. In concordance with
our results, Elzagheid et al. [25] found that the presence of
262 Virchows Arch (2016) 469:255–265
MUC2 significantly predicted longer disease-free survival and
disease-specific survival in 141 CRC patients across all stages.
Accordingly, Lugli et al. [10] reported on a large set of 1420
cases that loss of MUC2 is associated with the presence of
lymph nodemetastasis and with worse survival in bothMMR-
proficient and MMR-deficient tumors. In another study focus-
ing on stages II and III CRC, Kang et al. [26] likewise noted
significantly decreased overall survival when MUC2 expres-
sion was lost. However, other publications failed to identify a










































































































































































Fig. 4 Progression-free (a, p = 0.0034) and cancer-specific (b, p = 0.089)
survival of patients with stage II and III colorectal cancer related to the
extent of MUC2 expression (present vs. absent). Progression-free (c,
p = 0.015) and cancer-specific (d, p = 0.033) survival of patients with
stage II and III colorectal cancer related to the extent of MUC5AC
expression (high vs. low expression). Progression-free (e, p = 0.03) and
cancer-specific (f, p = 0.047) survival of patients with stage II and III
colorectal cancer related to the extent of MUC6 expression (high vs. low
expression)
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Literature data on the prognostic value of gastric type mu-
cins MUC5AC and MUC6 in CRC are limited. Our study is
the first to systematically analyze the prognostic impact of
MUC6 expression in CRC. The expression of MUC6 is rare:
We observed low expression of MUC6 in 27 % and high
expression of MUC6 in only 2 % of patients. However, when
MUC6 was present in the majority of cancer cells, affected
patients had an excellent prognosis. Therefore, we propose
that MUC6 (and MUC2) should be included in the panel of
molecular markers applied in prospective studies aiming at
risk stratification of CRC patients. Walsh et al. [27] identified
MUC6 expression in 33 % of CRCs. According to their and
other literature data [28], MUC6 and MUC5AC expression is
strongly associated with features of the serrated neoplasia
pathway. The impact on outcome was not analyzed in that
study. Interestingly, in vitro data generated in a study in-
vestigating pancreatic, colorectal, and breast cancer cell
lines suggest that MUC6 may inhibit invasion of tumor
cells through the basement membrane [29]. This may be a
possible mechanism to explain why patients with tumors
strongly expressing MUC6 have a favorable outcome.
The aberrant expression of MUC5AC in CRC was more
frequent than that of MUC6 in our study. It predicted favor-
able outcome, and this effect was particularly strong in pa-
tients with stage II and III disease. In agreement with our data,
a small study analyzing 41 cancer and 41 normal mucosa
specimens as well as 21 metastatic lymph nodes also found
that patients with tumors expressing MUC5AC had longer
disease-free and of overall survival [30]. Another study report-
ed a significant prognostic impact only in poorly differentiated
adenocarcinoma, but not in well-differentiated or mucinous-
type adenocarcinomas [31]. In a different study, MUC5AC
was marginally associated with survival, but statistically sig-
nificant only in stage IV disease. Hence, our data generally
support the limited evidence from literature in that MUC5AC
appears to be a significant, but moderately strong prognostic
parameter in CRC.
MMR status was significantly associated with the expres-
sion of MUC2, MUC5AC, and MUC6, which is in concor-
dance with literature data [27]. In MMR-proficient tumors, loss
of MUC2 expression and high expressions of MUC5AC and
MUC6 were associated with poor outcome, while no associa-
tion with survival was detected in patients with MMR-deficient
tumors. However, our cohort might not be suitable to prove the
lack of impact of mucin expression in MMR-deficient tumors
due to relatively small sample size in this subgroup of patients.
In bivariate Cox proportional hazards regression models, we
were able to confirm the prognostic impact of both MUC2 loss
and MUC5AC overexpression in intermediate stages II and III,
while MMR status had no impact on outcome. According to a
previous study, lack of MUC2 was found to be an adverse
prognostic factor in both MMR-proficient and MLH1-
negative CRC, but not in presumed HNPCC cases [10]. Data
analyzing the prognostic impact of MUC5AC and MUC6,
stratified by MMR status, have been lacking so far.
Divergent results in previous studies with respect to the
prognostic impact of different mucins, especially MUC1 and
MUC2, may be related to the methodology of assessment. We
aimed to assess mucin expression in a systematic and easily
reproducible fashion in a large number of CRC patients using a
high number of tumor tissue cores. However, in other studies,
different scoring systems have been used with different cutoffs
[10, 20, 22–24, 26, 30]. Also, different antibodies are usedwith
different staining protocols. Moreover, some authors have
scored mucin expression specifically at the invasive mar-
gin [21, 32]. This makes the comparison of studies diffi-
cult. Future (prospective) studies should aim to standard-
ize the methodology of assessment, before testing whether
MUC2, MUC5AC, and especially MUC6 expression can
be used to stratify patients regarding therapy decisions in
routine practice.
Our study has several other limitations. The analysis
of microsatellite instability was performed only by im-
munohistochemical staining of MMR proteins, not by
molecular analysis. Furthermore, there are general limi-
tations of retrospective studies, which we tried to control
by random selection of patients from a large institutional
database and by adherence to strict exclusion criteria.
Nonetheless, even considering these limitations, our data
strongly suggest that loss of MUC2 as well as aberrant
expression of MUC5AC and especially of MUC6 are
relevant prognostic indicators in CRC.
In conclusion, we found loss of MUC2 expression to be a
predictor of adverse outcome, while gain of aberrant
MUC5AC and particularly MUC6 expression was associated
with favorable outcome in CRC, especially in intermediate
stages II and III. Further prospective studies evaluating adju-
vant chemotherapy in stages II and III colon cancer should
include MUC2, MUC5AC, and MUC6 expression analysis
for patient stratification.
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